70. D. N. Slater. "The new world health organization–European organization for research and treatment of cancer classification for cutaneous lymphomas: A practical marriage of two giants," *Br. J. Dermatol.*, Nov. 2005;153(5):874–80.
71. X. F. Zhao, et al. "Pathogenesis of early leukemia and lymphoma," *Cancer Biomark*, 2011; 9(1-6):341–74.
72. C. M. Magro, et al. "Cutaneous immunocytoma: A clinical, histologic, and phenotypic study of 11 cases," *App. Immunohistochem. Mol. Morphol.*, Sept. 2004;12(3):216–24.
73. J. H. Cho-Vega, et al. "Primary cutaneous marginal zone B-cell lymphoma," *Am. J. Clin. Pathol.*, June 2006;125 Suppl:S38–49.
74. H. Takino, et al. "Primary cutaneous marginal zone B-cell lymphoma: A molecular and clinicopathological study of cases from Asia, Germany, and the United States," *Mod. Pathol.*, Dec. 2008;21(12):1517–26.
75. R. N. Hoover. "Lymphoma risks in populations with altered immunity: A search for mechanism," *Cancer Res.*, Oct. 1992 1;52(19 Suppl):5477s–8s.
76. A. Cozzio, et al. "Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma," *Leuk. Lymphoma*, May 2006;47(5):865–69.
77. R. Dummer, et al. "Phase 2 clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas," *Mol. Ther.*, June 2010;18(6):1244–47.
78. C. Yadav, et al. "Serum lactate dehydrogenase in non-Hodgkin's lymphoma: A prognostic indicator," *Indian J. of Clinical Biochemistry*, vol. 31,2 (2016): 240–42. doi:10.1007/s12291-015-0511-3.

Chapter 4

1. A. Büssing, et al. "Differences in the apoptosis-inducing properties of Viscum album L. extracts," *Anti-Cancer Drugs*, Apr. 1997, vol. 8, p. S9-S14.
2. *Vademecum of Anthroposophic Medicines.* Association of Anthroposophic Medicine in Germany (GAAD), 2019, chap. 5.4.
3. According to data gathered by The Plant List Project: http://www.theplantlist.org/browse/A/Santalaceae/Viscum/. Accessed Apr. 24, 2021.
4. C. W. Barney, et al, "Hosts of Viscum album," *Forest Pathology*, June 2007; 28(3):187–208.
5. *Vademecum of Anthroposophic Medicines.* Association of Anthroposophic Medicine in Germany (GAAD); 2019, chap. 5.7.1.
6. J. Wilkens and G. Böhm. *Mistletoe Therapy for Cancer* (Edinburgh: Floris Books, 2018), p. 53.
7. Per manufacturer data.
8. A. P. Simses-Wust, et al., "Sensitivity of primary cultures of breast cancer cells to different Iscador preparations," *Der Merkurstab,* 2011, 64(6);618.
9. T. Zuzak, et al. "Pediatric meduloblastoma cells are susceptible to viscum album (mistletoe) preparations," *Anticancer Research,* 2006, 26(5A). 3485–92.